Abstract:As an adoptive cellular therapy, Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has shown remarkable success in hematological malignancies, but only limited efficacy against solid tumors. Compared with blood cancers, solid tumors present a unique set of challenges that ultimately neutralize the function of CAR T-cells. One such barrier is antigen heterogeneity - variability in the expression of the antigen on tumor cells. Success of CAR T-cell therapy in solid tumors is unlikely unless almost all the tumor cells express the specific antigen that CAR T-cells target. A critical question for solving the heterogeneity problem is whether CAR T therapy induces bystander effects, such as antigen spreading. Antigen spreading occurs when CAR T-cells activate other endogenous antitumor CD8 T cells against antigens that were not originally targeted. In this work, we develop a mathematical model of CAR T-cell therapy for solid tumors that takes into consideration both antigen heterogeneity and bystander effects. Our model is based on in vivo treatment data that includes a mixture of target antigen-positive and target antigen-negative tumor cells. We use our model to simulate large cohorts of virtual patients to gain a better understanding of the relationship between bystander killing. We also investigate several strategies for enhancing the bystander effect and thus increasing the overall efficacy of CAR T-cell therapy for solid tumor.

What problem does this paper attempt to address?

The problems that this paper attempts to solve are the antigen heterogeneity and bystander effect problems encountered when using chimeric antigen receptor T - cell (CAR - T - cell) therapy in solid tumors. Specifically: 1. **Antigen heterogeneity**: Tumor cells in solid tumors are heterogeneous in antigen expression, that is, the expression levels of specific antigens on the surfaces of different tumor cells are inconsistent. This heterogeneity causes CAR - T cells to be unable to effectively recognize and kill all tumor cells, thereby reducing the treatment effect. 2. **Bystander effect**: Whether CAR - T cells can activate other endogenous anti - tumor immune cells (such as CD8 T cells) to attack tumor cells that are not directly targeted by CAR - T cells. If this bystander effect exists, it can improve the treatment effect of CAR - T cells on solid tumors. To study these problems, the author developed a mathematical model that takes into account antigen heterogeneity and the bystander effect and is simulated based on in - vivo experimental data. Through this model, the author hopes to better understand the role of the bystander effect in CAR - T - cell therapy and explore methods to enhance the bystander effect in order to improve the overall efficacy of CAR - T - cell therapy for solid tumors. ### Overview of the mathematical model Four different cell populations are considered in the model: - \(T_s\): Antigen - positive tumor cells - \(T_r\): Antigen - negative tumor cells - \(C\): CAR - T cells - \(B\): Bystander cells The model equations are as follows: \[ \frac{dT_s}{dt}=r_1T_s\left(1 - \frac{T_s + T_r}{K_1}\right)-D_BT_s - D_CT_s \] \[ \frac{dT_r}{dt}=r_2T_r\left(1 - \frac{T_s + T_r}{K_1}\right)-D_RT_r \] \[ \frac{dC}{dt}=v_C(t)-\gamma_CC-\mu_C\log\left(\frac{B + C}{K_2}\right)\frac{D^2_C}{k + D^2_C}-\omega_CCT_s \] \[ \frac{dB}{dt}=b-\gamma_BB-\mu_B\log\left(\frac{B + C}{K_2}\right)\frac{D^2_B}{k + D^2_B}-\omega_B(T_s + T_r) \] where: - \(D_B=\frac{d_B\left(\frac{B}{T_s}\right)^l}{s+\left(\frac{B}{T_s}\right)^l}\) - \(D_C=\frac{d_C\left(\frac{C}{T_s}\right)^l}{s+\left(\frac{C}{T_s}\right)^l}\) - \(D_R=\frac{d_B\left(\frac{B}{T_r}\right)^l}{s+\left(\frac{B}{T_r}\right)^l}\) These equations describe the interactions and dynamic changes among different cell populations, especially the effects of CAR - T cells and bystander cells on tumor cells. ### Main findings 1. **Relationship between CAR - T - cell dose and efficacy**: Increasing the dose of CAR - T cells does not guarantee a better treatment effect, especially when the antigen expression level is low. 2. **Virtual patient analysis**: By generating a virtual patient cohort, the author found that the maximum killing rate of bystander cells (\(d_B\)) is a key parameter for distinguishing responders from non - responders. Improving the killing ability of bystander cells can significantly improve the treatment effect. 3. **Enhancing the bystander effect**: By systematically increasing the maximum killing rate of bystander cells, the author found that this can significantly increase the proportion of responders, indicating that enhancing the bystander effect is to improve CA

Mathematical Modeling Insights into Improving CAR T cell Therapy for Solid Tumors: Antigen Heterogeneity and Bystander Effects

Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects

Computational model for tumor response to adoptive cell transfer therapy

In silico study of heterogeneous tumour-derived organoid response to CAR T-cell therapy

Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors

Mathematical model of CAR-T-cell therapy for a B-cell Lymphoma lymph node

CAR T cells for T-cell leukemias: Insights from mathematical models

Bistability and Bifurcations of Tumor Dynamics with Immune Escape and the Chimeric Antigen Receptor T-Cell Therapy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Spatiotemporal dynamics of tumor-CAR T-cell interaction following local administration in solid cancers

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy

Understanding the role of B-cells in CAR T-cell therapy in leukemia through a mathematical model

Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Optimising CAR T therapy for the treatment of solid tumors

Control-Oriented Models Inform Synthetic Biology Strategies in CAR T Cell Immunotherapy

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept

CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models